FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.7.21  |  FHIR Version n/a  User: [n/a]

4059511000001102: Nalidixic acid 300mg/5ml oral suspension 150 ml (product)

Status: current, Not sufficiently defined by necessary conditions definition status. Date: 01-May 2006. Module: SNOMED CT United Kingdom drug extension module

Descriptions:

Id Description Lang Type Status Case? Module
21895301000001110 Nalidixic acid 300mg/5ml oral suspension 150 ml (product) en Fully specified name Active Only initial character case insensitive SNOMED CT United Kingdom drug extension module
21895401000001119 Nalidixic acid 300mg/5ml oral suspension 150 ml en Synonym Active Only initial character case insensitive SNOMED CT United Kingdom drug extension module

4 descendants. Search Descendants:

Expanded Value Set

Outbound Relationships Type Target Active Characteristic Refinability Group Values
Nalidixic acid 300mg/5ml oral suspension 150 ml Has NHS dm+d (dictionary of medicines and devices) controlled drug category Controlled drug category No Controlled Drug Status true Inferred relationship Existential restriction modifier
Nalidixic acid 300mg/5ml oral suspension 150 ml Is a Virtual medicinal product pack true Inferred relationship Existential restriction modifier
Nalidixic acid 300mg/5ml oral suspension 150 ml Is pack of Product containing precisely nalidixic acid 60 milligram/1 milliliter conventional release oral suspension false Inferred relationship Existential restriction modifier
Nalidixic acid 300mg/5ml oral suspension 150 ml Has active ingredient Nalidixic acid false Inferred relationship Existential restriction modifier
Nalidixic acid 300mg/5ml oral suspension 150 ml VMP prescribing status (attribute) VMP valid as a prescribable product true Inferred relationship Existential restriction modifier
Nalidixic acid 300mg/5ml oral suspension 150 ml VMP non-availability indicator Available false Inferred relationship Existential restriction modifier
Nalidixic acid 300mg/5ml oral suspension 150 ml Has manufactured dose form Conventional release oral suspension false Inferred relationship Existential restriction modifier
Nalidixic acid 300mg/5ml oral suspension 150 ml Has VMP Product containing precisely nalidixic acid 60 milligram/1 milliliter conventional release oral suspension true Inferred relationship Existential restriction modifier
Nalidixic acid 300mg/5ml oral suspension 150 ml Has specific active ingredient Nalidixic acid true Inferred relationship Existential restriction modifier
Nalidixic acid 300mg/5ml oral suspension 150 ml Has dispensed dose form Conventional release oral suspension true Inferred relationship Existential restriction modifier
Nalidixic acid 300mg/5ml oral suspension 150 ml VMP non-availability indicator Not available true Inferred relationship Existential restriction modifier
Inbound Relationships Type Active Source Characteristic Refinability Group
Uriben 300mg/5ml oral suspension (Rosemont Pharmaceuticals Ltd) 150 ml Is a True Nalidixic acid 300mg/5ml oral suspension 150 ml Inferred relationship Existential restriction modifier
Nalidixic acid 300mg/5ml oral suspension (Rosemont Pharmaceuticals Ltd) 150 ml Is a True Nalidixic acid 300mg/5ml oral suspension 150 ml Inferred relationship Existential restriction modifier
Nalidixic acid 300mg/5ml oral suspension (Alliance Healthcare (Distribution) Ltd) 150 ml Is a True Nalidixic acid 300mg/5ml oral suspension 150 ml Inferred relationship Existential restriction modifier
Nalidixic acid 300mg/5ml oral suspension (Ennogen Healthcare Ltd) 150 ml Is a True Nalidixic acid 300mg/5ml oral suspension 150 ml Inferred relationship Existential restriction modifier

This concept is not in any reference sets

Back to Start